title: Norepinephrine-induced phasic activity in tail arteries from genetically hypertensive rats.
abstract: The effects of norepinephrine on contractile force development were studied in tail artery strips from spontaneously hypertensive stroke-prone (SHRSP) and Kyoto-Wistar normotensive rats (WKY). The strips were mounted in physiological salt solution between a fixed base and force transducers; isometric contractions were recorded. Norepinephrine-induced were characterized by fluctuations in contractile activity, whereas contractile responses in arteries from WKY remained constant with time. The magnitude and frequency of phasic responses in SHRSP arteries varied directly with increasing concentrations of norepinephrine (1.8 X 10(-9) to 1.8 X 10(-6) M). The phasic responses induced by norepinephrine in SHRSP arteries were reversed by the following experimental interventions: 1) 10(-4) M ouabain; 2) 20 degrees C; 3) potassium-free solution; 4) 1.0 mM BaCl2; 5) 20 mM KCl; 6) 30 mM tetraethylammonium chloride; 7) chloride-free solution; and 8) 10(-7) M D 600 (calcium channel blocker). It is proposed that the phasic contractile responses to norepinephrine in SHRSP are related to altered movements of calcium and potassium across the cell membrane. This study demonstrates a very distinct functional individuality in the arterial vascular smooth muscle cell membrane of SHRSP.
authors.forename: J H
authors.initials: JH
authors.lastname: Myers
authors.forename: F S
authors.initials: FS
authors.lastname: Lamb
authors.forename: R C
authors.initials: RC
authors.lastname: Webb
mesh_terms: D000818:Animals; D001158:Arteries / Q000503:physiopathology; D001794:Blood Pressure; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002463:Cell Membrane Permeability; D006973:Hypertension / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology*; D007473:Ion Channels / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009119:Muscle Contraction; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000378:metabolism; D009638:Norepinephrine / Q000494:pharmacology*; D010042:Ouabain / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D013623:Tail / Q000098:blood supply; D019789:Tetraethylammonium; D013757:Tetraethylammonium Compounds / Q000494:pharmacology
chemical_list: D002121:Calcium Channel Blockers; D007473:Ion Channels; D013757:Tetraethylammonium Compounds; D010042:Ouabain; D019789:Tetraethylammonium; D011188:Potassium; D002118:Calcium; D009638:Norepinephrine